Eli Lilly is set to make a significant impact on the global pharmaceutical market by introducing its blockbuster diabetes and weight-loss drug, Mounjaro, in key emerging economies by the latter half of 2025. This initiative is part of a larger strategy to meet the soaring global demand for effective obesity treatments.
About the Author
